Innoviva Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Innoviva Inc 's ROA in the third quarter of 2026?
Innoviva Inc achieved a return on average assets (ROA) of 9.93 % in its third quarter of 2026, which is below Innoviva Inc 's average return on assets, which stands at 16.91%.

ROA fell compared to the second quarter of 2026, despite the net income growth of % from the second quarter of 2026.

However, within the Healthcare sector 44 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 119, from total ROA ranking in the second quarter of 2026 at 276.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	45.12 %	67.85 %	46.17 %	25.41 %	16.08 %
Y / Y Net Income Change	-	-	-	707.36 %	7312.04 %
Net Income (TTM) in million	193	357	504	271	127
Return On Assets (TTM)	9.93 %	19.99 %	32.33 %	19.16 %	9.56 %
INVA's Total Ranking	# 119	# 276	# 643	# 1578	# 3068
Total Assets (TTM) in million	2,079	2,242	1,837	1,635	1,433
Seq. Total Assets Change	-7.28 %	22.09 %	12.32 %	14.14 %	7.24 %
Seq. Net Income Change	-	-	13.67 %	82.58 %	41.17 %

INVA's 5 Years Annual ROA >> Back to INVA Management Effectiveness >> Compare INVA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 24
Sector	# 45
Overall	# 201

Return On Assets Statistics
High	Average	Low
112.77 %	16.91 %	-35.68 %
(Dec 31 2018)		(Jun 30 2014)

Financial Statements
Innoviva Inc 's Assets	$ 2,079 million	INVA's Balance sheet
Innoviva Inc 's Income	$ -74 million	Quarterly INVA's Income Statement
INVA's Income by Division		See INVA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	56.44 %	3.27 %	2.36 %	32.97 %	-7.19 %
Total Assets in million	2,040	1,304	1,262	1,233	928
Y / Y Net Income Change	1059.22 %	-86.98 %	-18.41 %	-40.28 %	25.53 %
Net Income in million	271	23	180	220	369
Annual Return On Assets	13.29 %	1.79 %	14.24 %	17.86 %	39.77 %

INVA's 5 Years Annual ROA >> Back to INVA Management Effectiveness >> Compare INVA ROA to its Competitors

Comment on INVA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 13.29 % compared to prior year, due to annual net income growth of 1059.22 % to $271.17 million, while value of Innoviva Inc 's overall assets grew just by 56.44 % to $2,039.66 million, compared to $2,039.66 a year before.

More Return On Assets Ratios
INVA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INVA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INVA's Competitors
Subscribers only: Roa for Innoviva Inc 's Suppliers
Subscribers only: Return On Assets for INVA's Customers

You may also want to know
INVA's Roi	INVA's Inventory Turnover Ratio	INVA's Growth Rates	INVA's Dividend Comparisons
	INVA's Profitability Ratios	INVA's Asset Turnover Ratio	INVA's Dividend Growth
INVA's Roe	INVA's Valuation Ratios	INVA's Financial Strength Ratios	INVA's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %
Msa Safety Inc	11.01 %
Encompass Health Corporation	10.99 %

Date modified: 2026-11-08T13:39:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.